116 related articles for article (PubMed ID: 29621097)
21. Atypical and malignant meningiomas: a clinicopathological review.
Mahmood A; Caccamo DV; Tomecek FJ; Malik GM
Neurosurgery; 1993 Dec; 33(6):955-63. PubMed ID: 8134008
[TBL] [Abstract][Full Text] [Related]
22. Surgery for convexity meningiomas.
Morokoff AP; Zauberman J; Black PM
Neurosurgery; 2008 Sep; 63(3):427-33; discussion 433-4. PubMed ID: 18812953
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
24. Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis.
Spille DC; Heß K; Sauerland C; Sanai N; Stummer W; Paulus W; Brokinkel B
World Neurosurg; 2016 Sep; 93():346-54. PubMed ID: 27344043
[TBL] [Abstract][Full Text] [Related]
25. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
26. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
Silva CB; Ongaratti BR; Trott G; Haag T; Ferreira NP; Leães CG; Pereira-Lima JF; Oliveira Mda C
Int J Clin Exp Pathol; 2015; 8(10):13185-92. PubMed ID: 26722517
[TBL] [Abstract][Full Text] [Related]
27. [Multiple intracranial and intraspinal meningiomas successively discovered in the absence of neurofibromatosis: 2 cases].
Drouet A; Guilloton L; Pelissou-Guyotat I; Saint-Pierre G; Ribot C; Sindou M; Deruty R
Rev Neurol (Paris); 2001 Oct; 157(10):1264-9. PubMed ID: 11885519
[TBL] [Abstract][Full Text] [Related]
28. Genetic changes with prognostic value in histologically benign meningiomas.
Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
[TBL] [Abstract][Full Text] [Related]
29. Methylation markers of malignant potential in meningiomas.
Vengoechea J; Sloan AE; Chen Y; Guan X; Ostrom QT; Kerstetter A; Capella D; Cohen ML; Wolinsky Y; Devine K; Selman W; Barnett GH; Warnick RE; McPherson C; Chiocca EA; Elder JB; Barnholtz-Sloan JS
J Neurosurg; 2013 Oct; 119(4):899-906. PubMed ID: 23930849
[TBL] [Abstract][Full Text] [Related]
30. Treatment Response and Prognosis After Recurrence of Atypical Meningiomas.
Cao X; Hao S; Wu Z; Wang L; Jia G; Zhang L; Zhang J
World Neurosurg; 2015 Oct; 84(4):1014-9. PubMed ID: 26038336
[TBL] [Abstract][Full Text] [Related]
31. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
[TBL] [Abstract][Full Text] [Related]
32. [Meningiomas: new prognostic factors].
Sanz Esponera J
An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
[TBL] [Abstract][Full Text] [Related]
33. Is diffusion-weighted imaging useful in grading and differentiating histopathological subtypes of meningiomas?
Sanverdi SE; Ozgen B; Oguz KK; Mut M; Dolgun A; Soylemezoglu F; Cila A
Eur J Radiol; 2012 Sep; 81(9):2389-95. PubMed ID: 21723681
[TBL] [Abstract][Full Text] [Related]
34. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.
Perry A; Scheithauer BW; Stafford SL; Lohse CM; Wollan PC
Cancer; 1999 May; 85(9):2046-56. PubMed ID: 10223247
[TBL] [Abstract][Full Text] [Related]
35. Histopathological features to define atypical meningioma: What does really matter for prognosis?
Barresi V; Lionti S; Caliri S; Caffo M
Brain Tumor Pathol; 2018 Jul; 35(3):168-180. PubMed ID: 29671247
[TBL] [Abstract][Full Text] [Related]
36. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
[TBL] [Abstract][Full Text] [Related]
37. Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas.
Kim MS; Kim KH; Lee EH; Lee YM; Lee SH; Kim HD; Kim YZ
J Neurosurg; 2014 Nov; 121(5):1189-200. PubMed ID: 25148008
[TBL] [Abstract][Full Text] [Related]
38. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
39. Metabolomic and Lipidomic Characterization of Meningioma Grades Using LC-HRMS and Machine Learning.
Safari Yazd H; Bazargani SF; Fitzpatrick G; Yost RA; Kresak J; Garrett TJ
J Am Soc Mass Spectrom; 2023 Oct; 34(10):2187-2198. PubMed ID: 37708056
[TBL] [Abstract][Full Text] [Related]
40. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
